SecBot SecBot
SECBOTREPLAY Home › Report › ORKA

ORKA · Oruka Therapeutics announced a $500M underwritten public offering of…

Oruka Therapeutics, Inc. · PRESS-RELEASE filed Apr 27, 2026 at 16:17 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Apr 27, 2026 at 16:17 ET

Oruka Therapeutics announced a $500M underwritten public offering of common stock and pre-funded warrants, with an additional $75M option for underwriters. The proceeds will support its clinical-stage pipeline for psoriasis and inflammatory diseases. The offering represents roughly 15% dilution at current market cap, which is a negative signal for near-term stock price.

  • $500M underwritten public offering of common stock and pre-funded warrants
  • Underwriters have a 30-day option to purchase up to an additional $75M of shares
  • Leerink Partners, TD Cowen, Goldman Sachs, Stifel, and Guggenheim Securities are joint bookrunning managers
  • Shelf registration statement (Form S-3) became effective on April 10, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access